Phosphoglucose isomerase (PGI) is a multifunctional protein, which, inside the cell, functions as a housekeeping enzyme of glycolysis and gluconeogenesis and, outside the cell, exerts wholly unrelated cytokine properties. We have determined the structure of human PGI to a resolution of 1.6 A Ê using X-ray crystallography. The structure is highly similar to other PGIs, especially the architecture of the active site. Fortuitous binding of a sulphate molecule from the crystallisation solution has facilitated an accurate description of the substrate phosphate-binding site. Comparison with both native and inhibitor-bound rabbit PGI structures shows that two loops move closer to the active site upon binding inhibitor. Interestingly, the human structure most closely resembles the inhibitor-bound structure, suggesting that binding of the phosphate moiety of the substrate may trigger this conformational change. We suggest a new mechanism for catalysis that uses Glu357 as the base catalyst for the isomerase reaction rather than His388 as proposed previously. The human PGI structure has also provided a detailed framework with which to map mutations associated with non-spherocytic haemolytic anaemia.
Introduction
Glucose 6-phosphate isomerase (E.C. 5.3.1.9) (also known as phosphoglucose isomerase (PGI) and hexose phosphose isomerase), hereinafter referred to as PGI, has traditionally been considered a rather pedestrian enzyme of glycolysis and gluconeogenesis. In these pathways PGI interconverts glucose 6-phosphate (G6P) and fructose 6-phosphate (F6P), a reaction driven solely by the relative proportions of these sugars in the cytosol. The reaction proceeds via an acid-base mechanism involving a cis-enediol intermediate. 1 Kinetic data have suggested the participation of ionisable groups with pK a values of $6.5 and $9.5 in the catalytic mechanism. In one proposed mechanism these have been interpreted as being due to histidine and lysine residues acting as general acidbase catalysts in proton abstraction and sugar ringopening, respectively. 2 Two recent crystal structures of PGI from Bacillus, 3 and rabbit muscle 4 show that candidate histidine and lysine residues are present at the active site. The view of PGI as a simple housekeeping enzyme changed following a series of discoveries linking PGI to a variety of cytokine activities. In these guises PGI has been rediscovered as neuroleukin (NLK), 5 autocrine motility factor (AMF), 6 maturation factor (MF), 7 and, more recently, myo®-bril-bound serine proteinase inhibitor (MBSPI). 8 It now appears to act in a bewildering array of extracellular processes. 9 Thus, PGI is a product of T cells that promotes the survival of spinal and sensory neurons in vitro and stimulates the production of immunoglobulin by B cells. 10 It mediates the differentiation of human myeloid leukaemia cells 7 and is a tumour cell product that promotes cell migration. 6 The latter may be related to the high concentrations of PGI observed in the sera of patients with certain cancers. 11 Finally, PGI is the antigen in a mouse model of autoimmune rheumatoid arthritis 12 and is a major surface antigen in sperm agglutination. 13 How PGI acts in these varied systems remains a mystery, and is the subject of intense investigation. There are several apparent contradictions that remain to be resolved. The extracellular cytokine activities have been associated with a monomer of molecular mass of $55kD. 5, 8, 14, 15 This is contrary to the established dimeric structure of PGI, comprising identical subunits, each of molecular mass 63 kDa. In fact, a dimer of PGI is prerequisite for catalytic activity 16 and this is consistent with the active site of the enzyme being composed of polypeptide chains from both subunits 3, 4 
(C.D. & H.M., unpublished results
). Yet, at least in the case AMF, active site inhibitors of PGI also inhibit its cytokine activity. 6, 17 This apparent structural overlap between the catalytic and cytokine activities of PGI precludes the simplistic notion that the cytokine form of PGI is a truncated monomer, which is functionally distinct from the dimeric enzymatic form of PGI.
PGI is additionally important because de®ciency in this enzyme leads to non-spherocytic haemolytic anaemia, 18 an autosomal recessive genetic disorder caused by defects in pyruvate kinase (PK), triose phosphate isomerase (TPI) or PGI. Many of the PGI variants have now been characterised at the molecular level (for a review, see ref. 19 ). In the absence of detailed structural information for human PGI, however, the effect of these mutations on the phenotype cannot be assessed directly.
Structural investigations of PGI have been pursued for many years, 20 ± 22 but only recently has high resolution structural information for this enzyme become available from Bacillus, Here, we present the crystal structure of PGI from human, solved at 1.6 A Ê . At this resolution the active site is revealed in considerable detail. A sulphate ion from the crystallisation solution has bound to the active site where it mimics the binding of phosphate of the sugar substrates. In addition the structure provides a framework for the interpretation of mutations giving rise to haemolytic anaemia.
Results

Structure determination
Crystals were obtained over wells containing 2.2-2.6 M ammonium sulphate buffered with Tris-HCl (pH 8.0-8.5) or bis-Tris propane (pH 9.0).
The best crystals, and those used for the structural studies, grew over wells containing 2.6 M ammonium sulphate, 100 mM Tris (pH 8.5). These were of approximate dimensions 0.5 mm Â 0.5 mm Â 0.4 mm and had a multifaceted, diamond-like morphology. The crystals belong to space group P4 3 2 1 2 with cell dimensions a b 94.18 A Ê and c 136.14 A Ê . The diffraction of these crystals was excellent: the data collection statistics are shown in Table 1 . Based on the estimate of solvent content, 23 there is a single PGI monomer in the asymmetric unit. Interestingly, these crystals are essentially isomorphous with PGI crystallised from pig muscle, 20 which re¯ects the high degree of sequence identity between the two enzymes (93 %). The structure was therefore solved relatively easily by simple re®nement of the 2.5 A Ê structure of PGI from pig muscle (C.D. & H.M., unpublished results). Continuous electron density was observed for all of the main chain residues (Ala1 through to Glu557). Two peaks of signi®cant density were observed in the active site that could not be interpreted as water molecules. One of these had a tetrahedral shape and was assigned to a sulphate molecule. The other was extended with no visible branching and was interpreted as molecule of b-mercaptoethanol. The ®nal re®nement statistics are shown in Table 1 and the ®nal electron density in the active site region is shown in Figure 1 .
Structure description
The structure of human PGI is highly similar to that of the rabbit enzyme 4 (C.D. & H.M., unpublished data) and so will be described only brie¯y. The enzyme is comprised of two domains, traditionally termed large and small, 21 although they are fairly similar in size ( Figure 2 ). Each domain is R merge AEjI i À I m j/AEI i where I i is the intensity of the measured re¯ection and I m is the mean intensity of all symmetryrelated re¯ections. Figure 1 . Stereoview of the electron density map of human phosphosphoglucose isomerase set against coordinates of the ®nal re®ned structure, in ball and stick form. The area shown is the active site region. Bonds are coloured orange but those of the monomer generated by symmetry are coloured dark blue. Visible is this region is the bound sulphate ion (white bonds) and a molecule of b-mercaptoethanol (light blue bonds). The density is contoured at 1 s. This Figure was produced using BOBSCRIPT. 62 an aba sandwich. The polypeptide chain begins in the large domain, crosses to the small domain and then returns to the large domain. The small domain contains a ®ve-stranded parallel b-sheet surrounded on both sides by a helices. The large domain has a six-stranded mixed parallel/antiparallel b-sheet, also packed on both sides by a-helices. A striking aspect of the structure is a 45 residue extension at the C terminus which, in the dimer, wraps around the other monomer. On the opposite side of the molecule is another loop (residues 438-468), a``hook'', that also interacts principally with the opposite monomer. It is likely that both of these features help contribute to the very high stability of the PGI in denaturing conditions. 24, 25 The topology and assignment of secondary structure is shown in Figure 3 .
Worthy of particular mention is the nature of the protein core between the b-sheet of the large domain and the packing helices a16, a17 and a22, two of which, a16 and a22, are almost completely buried within the structure. In addition to the normal hydrophobic interactions typically observed in protein cores, this region is characterised by a preponderance of markedly polar residues, water molecules, and, most notably, three charged residues, Asp355, Asp404 and Lys496, all of which are totally buried. The charges are balanced by forming compensatory electrostatic interactions with each other, and with His335, which also has the potential to be charged. Interestingly, one of the mutations associated with haemolytic anaemia is found in this region, G323S (see Table 2 ). This residue is on the core facing side of helix a23. A larger side-chain at position 323 would project into the tight core and disrupt many of the packing interactions.
The position of the active site in PGI is known from previous crystallographic studies of the pig enzyme bound to 5-phosphoarabinonate (5-PA), 26 the rabbit enzyme bound to 6-phosphogluconate (6-PG) 4 and, very recently, the structures of Bacillus PGI complexed with two inhibitors. 17 It is located in the cleft between the large and small domain and is close to the subunit boundary.
Comparison with other PGIs
The fold of PGI from Bacillus is essentially the same as PGI from mammals. The main differences are that the Bacillus enzyme has a shorter N-terminal region and that the hook structure is unexpectedly positioned on the opposite face on the molecule relative to the C-terminal``arm'', whereas in mammalian PGIs these features are on the same side of the molecule. The active site regions are highly similar, concordant with these containing the most highly conserved residues.
Mammalian PGIs exhibit a high degree of sequence identity, typically 85-95 %, and this is also re¯ected at the structural level. Crystal structures of three mammalian PGIs are now known (rabbit, pig and human) and all have essentially identical folds. For instance, the RMS deviation in all main-chain atoms between the human and pig enzymes is only 0.47 A Ê , with the only differences occurring in a few surface exposed loops. Greater differences are observed when comparing the human and rabbit structures. In this case the equivalent RMS deviations are 0.68 A Ê for monomer A and 0.60 A Ê for monomer B of the native rabbit enzyme (C.D. & H.M., unpublished data). Interestingly, the principal differences map to the active site region. In the human structure, the position of helix a13, together with its preceding connecting loop, lies much closer to the active site cavity than in either monomer of the native rabbit structure (Figure 4) . Similarly, an adjacent loop between bc and a11 is also shifted away in the rabbit structure, although in this case the accompanying helix, a11, has shifted only slightly. The net effect of these differences is that, in the native rabbit enzyme, the active cavity is more open.
The human structure can also be compared with the structure of rabbit PGI containing the inhibitor, 6-PG. 4 The main-chain atoms of the human structure can be superimposed onto this structure with an RMS deviation of 0.517 A Ê for monomer A and 0.529 A Ê for monomer B, indicating again that overall, the two enzymes are highly similar. As before, the only signi®cant difference is a slight shift in the relative position of a13. In both monomers of the 6-PG-bound enzyme, the position of this helix is intermediate between that observed in the human Figure 2 . A ribbon representation of the structure of human phosphoglucose isomerase. The structure is colour ramped from blue at the N terminus to red at the C terminus. The active site is labelled and marked by the bound sulphate moiety, shown in CPK form. This Figure was produced using MOLSCRIPT. 63 and unliganded rabbit enzymes, but is closer to the position in the human structure ( Figure 4 ). The possible movement of this helix upon substrate binding is discussed below.
Active site
The high resolution of the human structure permits the most detailed view of the active site of PGI to date. Since the asymmetric unit in the human crystals is a monomer, the complete active site can only be visualized by generating a dimer using crystallographic symmetry. The active site comprises a number of residues that are totally conserved in all known sequences of PGI ( Figure 5 ). These include Lys210, Gln353, Glu357, Gln511, Lys518 and His388# (# denotes from the other subunit, generated by symmetry). All of these point into the active site cavity and make few bonding interactions with other residues. The same residues have also been identi®ed as active site residues in previous PGI structures. 3, 4 At one end of the active site is a constellation of threonine and serine residues that, as the inhibitor-bound rabbit enzyme shows, 4 are responsible for binding the phosphate group. Other prominent residues include Arg272, which makes extensive contacts within the active site (see Discussion), glycine residues 157 and 158, and Ile156.
Although our structure is of the native enzyme in the absence of substrate, fortuitous binding of components from the crystallisation medium has helped provide a clearer indication of how the substrate may bind. One of these is a sulphate ion (from the precipitant ammonium sulphate) which has bound to the substrate phosphate-binding site. It is held in place by potential hydrogen bond interactions with threonine residues 211 and 214, serine residues 159 and 209, the main-chain nitrogen atoms of Lys210 and Thr211, as well as with several water molecules ( Figure 6(a) ). An additional threonine, Thr217, is also involved via hydrogen bonds to a water molecule.
Another component of the crystallization solution, b-mercaptoethanol, has also bound in the active site. This molecule extends across the active site with its hydroxyl group pointing toward the 157-158 loop and, at the other end, with its sulphide oriented towards the e-amino group of Lys210. It makes only one direct contact with the enzyme, a potential hydrogen bond between its hydroxyl group and the main chain nitrogen of Gly158 ( Figure 6(b) ). Remaining contacts, to His388# and Lys210, are mediated through water molecules. The secondary structure assignments of human phosphoglucose isomerase. The a helices are shown as boxes, b strands as arrows and sections of 3/10 helix are also shown as small boxes. The secondary structure was calculated using PROMOTIF. 64 The Structure of Human Phosphoglucoseisomerase The active site of human PGI is populated by residues that are totally conserved in other species, including PGIs from bacteria. In Figure 7 a comparison of the active site of human PGI is made against inhibitor-bound rabbit and inhibitor-bound Bacillus enzyme. The active sites are indeed highly similar, especially between the mammalian enzymes. Although our structure is of the native enzyme, components of the crystallisation medium have bound to the active site, shedding light onto the possible mode of substrate binding. When compared with the inhibitor-bound rabbit enzyme, 4 there is a remarkable correspondence in the sulphate and phosphate positions (Figure 7(a) ) show- ing that the binding of sulphate has mimicked the phosphate group of the natural sugar substrate. As an example, the distance between O2 of the sulphate, or O2P of the phosphate, and the mainchain nitrogen atom of Lys210, is 2.84 A Ê in the former and 2.85 A Ê in the latter. Only one sulphate Figure 7 . A comparison of the active site of human PGI with those of (a) 6-phosphogluconate-bound rabbit PGI (PDB code 1dqr) and (b) 5-phosphoarabinonate-bound Bacillus enzyme (PDB code 1c7r). For the human and Bacillus structures, the dimers were generated by applying crystallographic symmetry to the monomer in each asymmetric unit. In both of these stereo representations the backbone of the human enzyme is coloured yellow, the active site residues are red and the bound sulphate and b-mercaptoethanol moieties are shown in ball-and-stick form with the bonds coloured light blue. For (a) the backbone of the rabbit enzyme is coloured orange, the active site residues are green and the bound inhibitor is shown as ball-and-stick with magenta bonds. Alpha carbon positions of both enzymes are shown in cpk form and numbered (both in black). Note the high similarity between the two structures including the close overlap of the sulphate and phosphate positions. In (b) the backbone and active site residues of the Bacillus enzyme are coloured blue. The bound inhibitor 5-phosphoarabinonate is shown as ball and stick with magenta bonds. The alpha carbon positions of both enzymes are shown as cpk, yellow for human and blue for Bacillus, with red numbers for human and blue for Bacillus. Marked is the position of the sulphate molecule in the human enzyme and the phosphate group of the inhibitor in the Bacillus structure. Note how these are located in different positions, with the phosphate in the Bacillus enzyme being coordinated by an entirely different set of interactions at the lower part of the active site.
oxygen atom (labelled O4 in Figure 6(a) ) is nonbonded and this is likely equivalent to O6 in the sugar substrate. A nearby lysine residue, Lys210, and an arginine residue, Arg95, probably act to accommodate the negative charge of the phosphate group. The precise nature of the interactions of the sulphate/phosphate, involving serine and threonine residues and several water molecules, explains the high speci®city of PGI for phosphorylated sugars. 27 Given this precision in both sulphate and phosphate binding, it is surprising to see that the phosphate group of 5-phosphoarabinonate (5-PA) has been positioned at the opposite end of the active site cavity in the structure of Bacillus PGI complexed with this inhibitor 17 ( Figure 7(b) ). As noted later, this has implications for the postulated reaction mechanism.
Converse to the situation with sulphate, the binding of b-mercaptoethanol in the active site cavity does not appear to imitate substrate binding. When compared to the position of 6-PG in the rabbit structure, b-mercaptoethanol lies in a perpendicular orientation and makes few speci®c contacts with the enzyme (Figure 7(a) ).
Substrate-induced movement of active site loops
Our structure of human PGI can also be compared with two previously determined structures of PGI from rabbit: of the native enzyme (C.D. & H.M., unpublished data) and of the 6-PG inhibitorbound enzyme. 4 Overall, the three structures are highly similar, indicating that few changes occur as a result of inhibitor binding. The only differences are seen in the positions of the helix a13 (and its preceding connecting loop) and the loop between bc and a11. In the inhibitor-bound rabbit structure both of these chains are signi®cantly closer to the active site than in the native rabbit structure. Since the bc-a11 loop mediates most of the interactions for phosphate binding, its apparent movement toward the active site upon binding substrate is logical. The accompanying movement of a13 with the bc-a11 loop may be explained by the strong hydrophobic interactions between these two elements, in which Phe212 appears to have a central role. If these changes are indeed a direct consequence of inhibitor binding, they may re¯ect the structural rearrangement that has been postulated to be the rate-limiting step for catalysis. 28 Interestingly, in our human structure the positions of these loops are much closer to those seen in the 6-PG-bound structure. This is highly suggestive that one of the two molecules observed bound in the active site cavity of the human structure triggers the movement of a13 and the bc-a11 loop. Of these, it is more likely that the binding of sulphate is responsible, since it mimics the substrate phosphate. These structural data imply that recognition of the phosphate group alone is suf®cient to promote the``active'' conformation of the enzyme after substrate binding. Structural movements arising from differences in crystal packing are unlikely, since both rabbit structures are solved from the same crystal form.
Complicating the picture is evidence that the various active site inhibitors of PGI may bind differently. In the recently published structure of Bacillus PGI complexed with 5-phosphoarabinonate, 17 not only does the inhibitor lie in a different orientation to that of 6-PG in the rabbit structure, but a different part of the active site has moved as a result of binding inhibitor (Figure 7(b) ). In this case residues 200-204, equivalent to 270-274 in mammals, have moved closer, apparently to bind with the phosphate group. In the human structure, this region is the active site loop between be and a14, containing two stretches of 3/10 helix. When compared to the two rabbit structures, however, this part of the structure shows no evidence for movement upon binding inhibitor. In the accompanying structure of Bacillus PGI bound to N-bromoacetylethanolamine phosphate (BAP), 17 the picture is closer to that seen in mammalian PGIs: the orientation of the bound inhibitor is the same as 6-PG in the rabbit enzyme and equivalent conformational changes occur (not shown).
It is clear that structural studies of PGI bound with the various inhibitors need to be carried out at a much higher resolution to enable a fuller understanding of the mode of substrate binding and of any consequent conformational changes.
Reaction mechanism
The isomerisation reaction is postulated to proceed by general acid/base catalysis via a cis-enediolate intermediate, generated by proton abstraction from C1 (for F6P) or C2 (for G6P) (see ref 29 and the observation that inhibitors of PGI mimic a cis-enediol structure. 30 Since the acyclic forms of glucose 6-phosphate and fructose 6-phosphate are present in solution in only trace amounts, 31 the enzyme is also presumed to catalyse ring opening. In support of this, PGI has an inherent anomerase activity that is catalytically distinct from the isomerisation reaction. 32 Chemical modi®cation studies have suggested several candidates for residues having a role in catalysis, including lysine, 33 33 and all of these residues are found in the active site pocket. Observed pK a values of 6.75 and pH 9.3 led researchers to propose that lysine and histidine residues were central to the reaction mechanism;.
2 the lysine to catalyse ring-opening and the neutral imidazole group as the base for proton abstraction. Based on the crystal structure of rabbit PGI bound to 6-PG, one group has proposed that Lys518 and His388 act as a general acid and base catalyst, respectively. 4 Central to this hypothesis is the role of Glu216, which forms a charge couple with His388 and may act to increase its basicity. How-ever, in this structure both His388 and Lys518 are too far away to interact directly with the C1 and C2 positions of the 6-PG inhibitor, requiring that the true substrate must bind somewhat differently. The structure of Bacillus PGI bound with 5-PA has been interpreted to propose an alternative scheme in which Lys420 (equivalent to Lys518 in mammals) acts as a base for ring opening, His308 (His388) is the base responsible for proton abstraction, and Glu285 (Glu357) acts as a general acid by donating a proton to the C1 carbonyl group. 17 The active site glutamate residue was identi®ed by using the inhibitor 1,2-anhydro-D-mannitol-6-phosphate. 37 With the orientation of 5-PA in this model, His308 is indeed well placed to act as the base at C1/C2. However, the existence of two binding modes for PGI inhibitors, that this model necessitates, is hard to reconcile both with the absolute speci®city of PGI for phosphorylated sugars 27 and the highly precise interactions of the sulphate moiety observed in our human structure.
In the rabbit 6-PG structure Glu357 is better placed than His388 to abstract a proton from the C1 and C2 positions of the inhibitor. Moreover, the choice of a bidentate residue for a suprafacial 1,2 hydrogen transfer is a logical one. We introduce, therefore, a third possible scheme in which Glu357 is the base catalyst ( Figure 8 ). As such it may be similar to the role Glu165 plays in triosephosphate isomerase (TPI) 38 where the position of the carboxylate group with respect to C1 and C2 carbon atoms of the substrate is critical. As with Glu165 in TPI, the pK a of Glu357 must be raised by two to three pH units for it to act as an effective base. How this is achieved is uncertain, particularly with the adjacent arginine residue (Arg272), though it may be a result of this residue being buried in a hydrophobic environment. Gln511 is positioned such that it may have a role in the mechanism by stabilising the cis-enediol intermediate via hydrogen bonding interactions. The nature of the residue responsible for ring opening is more questionable. One possibility is Lys518, via a general acid mechanism in which its proton is donated to the ring oxygen atom. 2 Alternatively, His388 may serve as a base catalyst for ring opening: its basicity being enhanced by the charge couple with Glu216. There is good evidence that His388 acts as a base in catalysis, 39 but since these experiments have not separated the isomerase and anomerase activities of PGI, it could equally likely act as a base in ringopening. Whatever its precise role, His388 is clearly an important residue, as evidenced by its mutation to Ala, Asn and Gln leading to a 1000-fold lower isomerase activity of Bacillus PGI 39 and the existence of the Calden variant of haemolytic anaemia. 40 The role of Arg272 may be to stabilize the negative charge on the enediolate intermediate, as has been proposed. 4 Alternatively, by making numerous contacts with other components of the active site (see Figure 9 (b)), it may serve a structural role by maintaining the correct architecture of the active site, including the position of Glu357. Figure 8 . A proposed reaction mechanism for phosphoglucoseisomerase. In this scheme Glu357 is the base responsible for proton abstraction from the C1 and C2 positions of fructose 6-phosphate and glucose 6-phosphate respectively. After substrate binding, the ®rst step is ring opening, which here is shown to be catalysed by the acid group Lys518, but could equally be likely catalysed by His388. This results in the loss of a proton from the C1 hydroxyl group to the solvent, forming a carbonyl group. Glu357 then abstracts a proton from the C2 position of G6P, causing electrons to¯ow towards the C1 carbonyl. The resulting negative charge attracts a proton from the solvent, forming the cis-enediol intermediate. Glu357 then donates back a proton to the C1 position. The resulting electron¯ow towards Glu357 leaves a carbonyl group at C2. In the ®nal step Lys518 (or His388) abstracts a proton from the sugar ring oxygen leading to ring closure and the reestablishment of a hydroxyl group at C2. Which of these mechanisms is shown to be correct, or indeed whether a wholly different mechanism is at play, awaits more detailed studies. The presence of multiple charges in the active site of PGI increases the potential for charges to be delocalised over more than one ionizable group, resulting in cooperative pK a effects, and complicating any proposed mechanism.
Mutations associated with haemolytic anaemia
PGI is an essential enzyme and its inactivation in mice is embryonic lethal. 41, 42 PGI de®ciency in humans is an autosomal recessive genetic disorder resulting in nonspherocytic haemolytic anaemia. Many of the mutations in PGI associated with haemolytic anaemia have now been characterised at the molecular level (for a review, see ref. 19) . These mutations are all homozygotes or compound heterozygotes of partially inactive enzyme alleles. Although the potential effect of some of these was discussed previously in the context of the rabbit enzyme, 4 the high-resolution structure of the human enzyme is more relevant for their understanding, especially where contacts are mediated via water molecules. The roles of these residues and the likely effect that their mutation has had upon the PGI structure has been examined in detail ( Table 2 ). The distribution of the mutations within the PGI fold is shown in Figure 9 (a). The mutations can be classi®ed loosely into three groups: (a) those that impact the precise structure of the enzyme, S; (b) those that disrupt or alter a dimerdimer contact, D.I.; and (c) those of residues at the active site, which may have a role in catalytic function, A.S. Many of these mutations illustrate just how critical the precise three-dimensional structure is for correct function. The majority of the mutations disrupt key interactions that contribute directly or indirectly to the active site architecture. Some of these are shown in Figure 9 . The importance of the two 3/10 helical segments in the active site (residues 270-274 and 277-279) is illustrated by several different variants. The Arg272His mutation (Figure 9(b) ) would remove an essential residue that makes contacts between the ®rst 3/10 helix and two other active site components, the loop between helices a22 and a23, and helix a17. These elements contain residues that point into the active site and likely have a role in substrate binding or catalytic function (see above). In particular helix a17 is highly conserved: one side of this helix contains Glu357 and Gln353, both of which project into the active site. The other side of this helix packs into the atypical protein core, described earlier, in which Asp355 has a prominent role. The mutations Val100Met, Glu494Lys and Ala299Pro also potentially disrupt the active site architecture by altering the critical interactions between helices a22, a7, and a6 and including the 3/10 helix between residues 270 and 274 (Figure 9(c) ). The position of the active site helix a17 is likely to be altered as a result of two other mutations, Thr374Arg and Thr4Ile (Figure 9(d) ). The mutation at 374 would break the hydrogen bond from the threonine side-chain to the carbonyl group of Lys361, which links b4 and a17. The Thr4Ile mutation would remove the potential hydrogen bond between the N-terminal helix and the a17-b4 loop. An example of a critical dimer-dimer interaction is provided by the Arg346Cys mutation, which occurs in several variants (Figure 9(e) ). This residue forms an electrostatic interaction across the dimer interface with Glu381# and, vice versa, Arg346# interacts with Glu381. There is also a network of water molecules linking all four residues. Nearby is a second mutation, Gln342Arg, which would also disrupt a dimer interface interaction, with Asn185#. As seen in Figure 9 (e), the active site is very close to the sites of both of these mutations.
Two of the mutations are of active site residues and fall into the last category. The Gly158Ser mutation would lead to a bulkier side-chain projecting into the active site and would probably restrict substrate binding (see Figure 5) . Alternatively, removal of the glycine residue may reduce the conformational¯exibility of the active site loop that is highly populated with glycines (residues 155-158). His388 almost certainly has an important role in catalysis (see above) and its replacement by an arginine would lead to reduced catalytic function (see Figure 5 ).
How does PGI act as a cytokine?
In order to decipher how PGI acts as a cytokine, there are three key questions to be answered: (1) what exactly is the nature of the cytokine version of PGI; (2) how does the PGI cytokine bind to its putative receptor and (3) how is PGI secreted without a leader peptide? Answering these reveals contradictions and ambiguities that remain to be resolved.
On the ®rst of these questions, the cytokine version of PGI has been reported to be a monomer of The Structure of Human Phosphoglucoseisomerase approximate molecular mass 55 kDa. 5, 7, 8, 43 This is at odds with biochemical and structural data showing that PGI exists as a dimer with a subunit mass of 63 kDa. As the available crystal structures show, PGI is a tight dimer with numerous and highly speci®c contacts between the subunits. Two structural features, the hook between residues 438 and 469 and C-terminal extension, both of which wrap around the partner monomer, likely contribute to the high stability of the enzyme. Moreover, it is well established that the dimer is necessary for catalytic function 16 and the structure shows very clearly why this is the case. In a monomeric enzyme the contribution of His388 from the other subunit would be absent and it is likely that the resulting protein would be, at the very least, catalytically impaired. The importance of the dimer, at least for catalytic function, is also suggested by those instances of haemolytic anaemia arising through mutations of residues mediating dimerdimer contacts. Also at odds with the existence of a monomeric cytokine PGI is the evidence that AMF, 6, 7 neuroleukin, 44 MF 7 and MBSPI, 8 all manifest PGI activity. Indeed several of these reports also demonstrate that the commercially available rabbit muscle enzyme itself possesses cytokine activity. Furthermore, two recent papers reveal that enzymatically active recombinant PGI has full autocrine motility factor activity. 45, 46 Given this evidence, it is hard to envisage PGI existing as anything other than a dimer, suggesting that smaller or monomeric forms of the protein may not be directly related to cytokine activities. Nevertheless it will be essential to establish unambiguously the true molecular mass and oligomeric state of the cytokine versions of PGI.
To function as an extracellular cytokine PGI must bind to a receptor. One group isolated a cDNA clone for a putative AMF receptor using a monoclonal antibody with AMF-agonistic activity. 15 The receptor was more recently described as a putative seven transmembrane domain protein. 47 The high-resolution structure of PGI, however, gives few clues as to how this enzyme may bind to such a receptor. There are no striking hydrophobic areas on the surface of the enzyme, and since the protein is so well conserved overall within mammals, clusters of highly conserved residues on the surface cannot readily be identi®ed. An alternate possibility is that if the cytokine PGI is indeed a monomer, the remnant active site mediates receptor binding, perhaps by binding to sugar moieties on the glycoprotein receptor molecules that are similar to the substrate sugars. 48 It should be noted, however, that PGI binds sugar substrates with millimolar af®nities, whereas the cytokine activities of PGI are observed at protein concentrations of less than nanomolar. The main contribution from the adjacent monomer to the active site is the 3/10 helix (residues 384-389). Were this to be removed, the active site would be more exposed but most of the residues responsible for binding the substrate would remain. Indeed, matrix-bound monomers of PGI can still bind substrate. 16 In support of this hypothesis, several speci®c inhibitors of PGI activity, which bind to the active site, also abolish AMFinduced cell motility with no effect on basal migration, 6, 17 suggesting that there is structural overlap of the regions responsible for the catalytic and cytokine functions of PGI. The alternative explanation is that these inhibitors may induce subtle conformational changes that alter binding to the receptor. The fact that PGI from Bacillus manifests AMF activity also argues for a role of the active region in cytokine function, 3, 17 since the most conserved regions lie at the active site. Identi®cation of the precise epitope responsible for receptor binding is a major priority for future investigations. No detailed biochemical studies of ligand-receptor binding have yet been published, but a ®rst step is the recent demonstration of speci®c binding of biotinylated rabbit PGI to intact mammalian cells. 49 The third question concerns the mechanism by which PGI is secreted from the cell. PGI lacks a leader sequence and is probably released directly from the cytoplasm. Cell lysis and necrosis could lead to release, but a non-classical secretory pathway may also be involved. 50 One report has linked the secretion of AMF with the phosphorylation of Ser183. 46 This residue is located at the base of a deep cleft, so it is hard to envisage a protein kinase gaining access to such a buried residue. Whatever the mechanism, given the resistance of folded PGI to dissociation and denaturation, it is likely that the active dimer is secreted intact across the plasma membrane.
Materials and Methods
Protein expression and purification A 1.7kb DNA fragment encoding human PGI was prepared by PCR in a manner exactly parallel to that described for the rabbit enzyme. 51 Flanking PCR primers changed the 5 H end, so that the methionine start codon was within a unique NdeI restriction enzyme recognition site, and so that the stop codon was replaced by six histidine codons followed by a new UAA stop codon and an EcoRI recognition site. The PCR primers were used to amplify the open reading frame of human PGI using minimal cycle number and high ®delity Vent DNA polymerase (NE BioLabs Inc.). Template was the human adult brain cDNA clone 184111 (IMAGE Consortium) identi®ed from a BLAST search of the human EST database as EST H30758. The ampli®ed DNA was subcloned into the bacterial expression vector pET5a as an NdeI to EcoRI fragment and expressed in Escherichia coli BL21DE3pLysS (Stratagene Inc.). The bacterial cultures were induced with 0.5 mM i-PTG for three hours at 30 C. Cell pellets were collected by low speed centrifugation, lysed by sonication without protease inhibitors, and clari®ed by high speed centrifugation. The soluble supernatants were bound to NiNTA agarose (Qiagen Inc) and washed and eluted according to the manufacturer's standard protocol. The material eluting in 0.25 M imidazole was >95 % homogenous as estimated from Coomassie blue staining of the protein on denaturing, reducing 12.5 % polyacrylamide gels. Recovery was approximately 50 mg per litre of bacterial culture. PGI was concentrated and equilibrated with phosphate-buffered standard saline using Centricon-30 ultra®ltration (Amicon). The puri®ed protein was stable, had kinetic properties very similar to those of the rabbit muscle enzyme, and was free of detectable bacterial endotoxin (Hill, Li, and Chirgwin, in preparation).
Crystallisation
Using Centricon microconcentrators (Amicon), the protein was exchanged into buffer containing 15 mM Hepes at pH 7.5 and 2 mM b-mercaptoethanol and concentrated to approximately 4 mg/ml. Crystals were grown by the hanging drop method in which 3 ml of well solution was mixed with 3 ml of the protein solution. A variety of crystallisation conditions were tested.
Data collection
Crystals of hPGI were cryo-frozen by passing through a solution containing 100 mM Tris (pH 8.5), 2.6 M ammonium sulphate and 30 % (v/v) glycerol, added as cryoprotectant. Diffraction data extending to 1.62 A Ê resolution were collected at Daresbury SRS, station PX7.2 (wavelength 1.488 A Ê ) on a Mar 345 image plate. The data were collected in two passes. For the low-resolution data the crystal-to-plate distance was 222.7 mm and 50 images were collected each with an exposure time of two minutes per 1 oscillation frame. For the high-resolution pass the crystal-to-plate distance was 120 mm and 100 images were collected with an exposure time of two minutes per 0.6 oscillation frame. The data were integrated using DENZO and scaled with SCALEPACK. 52 
Structure determination
The structure of hPGI was solved using the re®ned structure of pig muscle PGI (C.D. & H.M., unpublished results). After replacing the sequence to correspond to that of human PGI, the initial model was subject to several cycles of rigid body re®nement followed by a round of conventional re®nement, both using XPLOR. 53 Further improvements to the model were made by cycles of manual rebuilding, using O, 54 and crystallographic re®nement with REFMAC. 55 Water molecules were added using ARPP 56 and checked manually. Since the ®rst residue of native PGI from rabbit is known to start with an alanine residue, 57 the ®nal model is numbered 1 to 557. Incomplete density was observed for the nonnative methionine residue at the N terminus and so was omitted from the model.
In published sequences of human PGI there is a conict at position 157, with one entry listing a glycine 58 whereas others show a valine 59, 60 (accession K03515, M. Gurney, unpublished). Notably, in other species of PGI this residue is totally conserved as a glycine. When re®ned as a valine, jF o j À jF c j difference maps revealed a large peak of negative density around the side-chain and the phi/psi angles also fell within a disallowed region of the Ramachandran plot. We have therefore modelled this residue as a glycine residue.
Structure superimpositions were performed using the CCP4 program LSQKAB. 61 In the case of the rabbit enzyme (PDB code 1dqr) all atoms were included, whereas for the Bacillus structure (PDB code 1c7r) only active site loops (with side-chains) were included.
Protein Data Bank accession codes
The coordinates have been submitted to the RCSB with accession code 1IAT.
